The results showed that there were a total of 167 signaling pathways intervened by GJR in AD (q value < 0.05), mainly involving Pathways in cancer, Prostate cancer, Endocrine resistance, and EGFR tyrosine kinase inhibitor resistance, Proteoglycans in cancer, Serotonergic synapse, PI3K-Akt signaling pathway, Arachidonic acid metabolism, Bladder cancer, Central carbon metabolism in cancer (Figure 3G). This evidence concerns the gene AKT1 and Alzheimer disease.